TYRA

MKT CAP:$2B

Tyra Biosciences, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$36.69+$9.90 (+36.95%)

Apr 23, 2026

Company Details

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor...

CEO

Todd Harris

IPO Date

Sep 15, 2021

Website

www.tyra.bio

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$120M

EPS (Diluted)

-$2.01

Free Cash Flow

-$95M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 2, 2026

$0EPS -$2.01

Q4 2025

Mar 2, 2026

$0EPS -$0.57

Q3 2025

Nov 5, 2025

$0EPS -$0.50

Q2 2025

Aug 14, 2025

$0EPS -$0.47

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$15M
Q2 22	$0	$0	-$15M
Q3 22	$0	$0	-$14M
Q4 22	$0	$0	-$15M
Q1 23	$0	$0	-$14M
Q2 23	$0	$0	-$16M
Q3 23	$0	$0	-$24M
Q4 23	$0	$0	-$26M
Q1 24	$0	-$122.0K	-$22M
Q2 24	$0	-$126.0K	-$24M
Q3 24	$0	$0	-$29M
Q4 24	$0	$0	-$30M
Q1 25	$0	$0	-$32M
Q2 25	$0	$0	-$31M
Q3 25	$0	$0	-$33M
Q4 25	$0	-$132.0K	-$37M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$9M	-$9M
Q2 22	-$17M	-$17M
Q3 22	-$12M	-$12M
Q4 22	-$12M	-$12M
Q1 23	-$10M	-$10M
Q2 23	-$10M	-$10M
Q3 23	-$17M	-$17M
Q4 23	-$14M	-$14M
Q1 24	-$22M	-$22M
Q2 24	-$10M	-$11M
Q3 24	-$18M	-$18M
Q4 24	-$20M	-$20M
Q1 25	-$25M	-$25M
Q2 25	-$24M	-$24M
Q3 25	-$22M	-$22M
Q4 25	-$24M	-$24M

Capital Expenditures

Quarter	CapEx
Q1 22	$239.0K
Q2 22	$251.0K
Q3 22	$48.0K
Q4 22	$21.0K
Q1 23	$41.0K
Q2 23	$43.0K
Q3 23	$83.0K
Q4 23	$603.0K
Q1 24	$136.0K
Q2 24	$470.0K
Q3 24	$52.0K
Q4 24	$6.0K
Q1 25	$14.0K
Q2 25	$31.0K
Q3 25	$39.0K
Q4 25	$57.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+252.3%
Q2 22	—	+180.1%
Q3 22	—	+105.6%
Q4 22	—	+51.2%
Q1 23	—	-3.4%
Q2 23	—	+3.8%
Q3 23	—	+75.6%
Q4 23	—	+70.7%
Q1 24	—	+55.7%
Q2 24	—	+46.9%
Q3 24	—	+19.4%
Q4 24	—	+16.0%
Q1 25	—	+42.7%
Q2 25	—	+33.7%
Q3 25	—	+15.2%
Q4 25	—	+22.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	—
Q2 22	$3M	—
Q3 22	$1M	—
Q4 22	$3M	—
Q1 23	$2M	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$4M	—
Q1 24	$4M	—
Q2 24	$4M	—
Q3 24	$8M	—
Q4 24	$7M	—
Q1 25	$6M	—
Q2 25	$6M	—
Q3 25	$8M	—
Q4 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$10M	$5M
Q2 22	$12M	$3M
Q3 22	$11M	$3M
Q4 22	$10M	$5M
Q1 23	$10M	$4M
Q2 23	$12M	$4M
Q3 23	$19M	$5M
Q4 23	$21M	$5M
Q1 24	$17M	$5M
Q2 24	$18M	$6M
Q3 24	$23M	$6M
Q4 24	$22M	$8M
Q1 25	$25M	$7M
Q2 25	$24M	$7M
Q3 25	$25M	$7M
Q4 25	$28M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$292M	$0	$292M
Q2 22	$275M	$0	$275M
Q3 22	$263M	$0	$263M
Q4 22	$251M	$0	$251M
Q1 23	$242M	$0	$242M
Q2 23	$232M	$0	$232M
Q3 23	$216M	$0	$216M
Q4 23	$58M	$145M	$203M
Q1 24	$254M	$128M	$382M
Q2 24	$99M	$274M	$374M
Q3 24	$104M	$256M	$360M
Q4 24	$92M	$249M	$341M
Q1 25	$101M	$218M	$319M
Q2 25	$98M	$198M	$296M
Q3 25	$62M	$213M	$275M
Q4 25	$77M	$179M	$256M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	42M	+0.6%	+84.8%
Q2 22	42M	+0.5%	+13.5%
Q3 22	42M	+0.5%	+358.3%
Q4 22	42M	+0.5%	+2.2%
Q1 23	42M	+0.4%	+2.0%
Q2 23	43M	+0.5%	+1.9%
Q3 23	43M	+0.7%	+2.1%
Q4 23	43M	+0.2%	+1.8%
Q1 24	52M	+21.6%	+23.2%
Q2 24	59M	+12.3%	+37.8%
Q3 24	59M	+0.4%	+37.3%
Q4 24	59M	0.0%	+37.0%
Q1 25	59M	+0.8%	+13.6%
Q2 25	60M	+0.4%	+1.5%
Q3 25	60M	+0.2%	+1.4%
Q4 25	60M	-0.1%	+1.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	25
Q2 22	$0	25
Q3 22	$0	25
Q4 22	$0	38
Q1 23	$0	38
Q2 23	$0	38
Q3 23	$0	38
Q4 23	$0	49
Q1 24	$0	49
Q2 24	$0	49
Q3 24	$0	49
Q4 24	$0	60
Q1 25	$0	60
Q2 25	$0	60
Q3 25	$0	60
Q4 25	$0	740K

Revenue / Employee